Avexa's Apricitabine Clinical Trial Update
MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian
biotechnology company Avexa (ASX:AVX) announced today the
completion of apricitabine's controlled, double blinded phase which
represents the first 24 week segment of its Phase IIb trial.
Patients have now progressed into the open-label...
Avexa Reports Positive Phase IIb Result
...AVX) today announced highly
successful results from its Phase IIb trial for apricitabine
ATC is Avexa's novel nucleoside reverse transcriptase inhibitor
(NRT...or antibiotic-resistant bacterial
infections. The Company's lead program is apricitabine
has recently successfully completed the 21 day dosing of its Ph...